Clinical Research

Breast cancer treatment meets trial endpoint

Saturday 23 October 2021
Country
Italy

An experimental breast cancer treatment for patients with estrogen receptor positive and HER2 negative breast cancer has met the primary endpoint in a Phase 3 trial paving the way for regulatory submissions in the US and Europe in 2022, the developers Menarini Group and Radius Health Inc, announced on 20 October.

Antibody therapy works against Covid-19

Wednesday 13 October 2021
Country
United Kingdom

An antibody combination therapy has shown a statistically significant reduction in severe Covid-19 or death among patients with mild to moderate disease, the developer AstraZeneca Plc reported on 11 October. This follows the successful trial of a small molecule antiviral agent produced by Merck & Co Inc and Ridgeback Biotherapeutics LP for a similar patient population which was announced on 1 October. Using different agents, the two trials both achieved efficacy rates of 50% compared with placebo.

Anti-viral medicine effective against Covid-19

Saturday 2 October 2021
Country
United States

An anti-viral medicine developed jointly by Merck & Co Inc and Ridgeback Biotherapeutics LP, has reduced the risk of hospitalisation or death in patients with Covid-19 by 50% compared with placebo, the two companies announced on 1 October. A Phase 3 trial of the drug, molnupiravir was stopped early and the developers plan to seek an emergency use authorisation from the US Food and Drug Administration in order to get the medicine onto the market quickly. Molnupiravir is a small molecule ribonucleoside analogue that inhibits the replication of the SARS-CoV-2 virus.

Keytruda meets endpoint in liver cancer

Thursday 30 September 2021
Country
United States

A Phase 3 study of Keytruda (pembrolizumab) in Asian patients with advanced hepatocellular carcinoma met is primary endpoint of overall survival, the developer Merck & Co Inc announced on 27 September. Patients in the trial had previously been treated with sorafenib, an approved treatment for kidney and liver cancers. Hepatocellular carcinoma is the most common type of primary liver cancer.

Positive data for Lynparza in prostate cancer

Thursday 30 September 2021
Country
United Kingdom

Lynparza (olaparib) has generated more positive data in prostate cancer, this time as a potential first-line treatment for men with metastatic castration-resistant prostate cancer with or without mutations in homologous recombination repair (HRR) genes. A Phase 3 trial comparing Lynparza against placebo when given in addition to the prostate cancer drug abiraterone showed a statistically significant improvement in radiographic progression-free survival, the developers AstraZeneca Plc and Merck & Co Inc, announced on 24 September.

Positive data for Arecor insulin treatment

Monday 20 September 2021
Country
United Kingdom

A novel form of insulin that is intended to accelerate absorption of the hormone by patients with Type 1 diabetes has met the primary endpoint of non-inferiority in a Phase 1 trial compared with NovoRapid, a standard of care. Arecor Therapeutics Plc, the developer, announced the results on 20 September. AT278 is an ultra-concentrated formulation that has been designed to speed absorption of insulin post injection even when delivered at a high concentration.

Astellas reports death of gene therapy trial participant

Wednesday 15 September 2021
Country
Japan

Astellas Pharma Inc has reported the death of a participant in a clinical trial of a gene therapy for the treatment X-linked myotubular myopathy, a rare neuromuscular disease caused by mutations in the MTM1 gene. The participant, who developed an adverse event during the trial, passed away on 9 September. “The cause of death is still pending,” the company announced on 14 September.

Clinical hold on gene therapy trial

Wednesday 15 September 2021
Country
United States

The US Food and Drug Administration has placed a clinical hold on a Phase 1/2 trial of a gene therapy for adults with phenylketonuria, a genetic disorder caused by the deficiency of an enzyme needed to break down an amino acid in certain foods. The clinical hold was based on findings from a preclinical study showing that six out of seven mice receiving the highest dose of the therapy developed liver tumours. One of the tumours was cancerous. BioMarin Pharmaceutical Inc, the developer, announced the clinical hold on 6 September.

Rilzabrutinib study in pemphigus fails to meet endpoint

Thursday 9 September 2021
Country
France

A Phase 3 trial evaluating the Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib in pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints, the developer Sanofi SA announced on 9 September. No new safety signals were identified.

Autism trials stopped early

Tuesday 7 September 2021
Country
France

Two Phase 3 trials of bumetanide, which was being investigated in children and adolescents with autism spectrum disorder, have been discontinued due to a lack of efficacy, the sponsors Les Laboratoires Servier SAS and Neurochlore SAS announced on 7 September.